Potential Analysis of Human DNA Vaccines Market Value Expected to Show $9,337 Mn by 2030 : Allied Market Research

"A DNA vaccine may enhance antibody response to the gene products and expand the applications of the gene vaccines."

According to a new report published by Allied Market Research, titled, Potential Analysis of Human DNA Vaccines Market by Forecast Scenario: Global Opportunity Analysis and Industry Forecast, 2020-2030, the global potential analysis of human DNA vaccines market is expected to account for $3,762 million by 2020 and reach $9,337 million by 2030, growing at a CAGR of 9.5% from 2020 to 2030. Key opportunities for market expansion include the high need for vaccines for immunization & prevention of infectious diseases.

Send Enquiry on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/2309

A DNA vaccine is a small, circular DNA plasmid that encodes one or more protein antigens under the control of a promoter to produce a specific immune response against disease. DNA vaccines are the third-generation vaccines specifically designed to overcome the unsought properties of conventional vaccines. Increase in vulnerability of the population to infectious diseases and rise in number of antibiotics-resistant pathogens have created the need for effective and low-cost vaccination, which would provide long-lasting immunity. DNA vaccines have potential advantages over traditional methods, for example, low risk of infection, easy transportation, and stability at room temperature. The potential of global human DNA vaccines market is expected to be rapid, owing to property of DNA vaccines of specific antigen targeting, reduced risk of infection compared to conventional vaccines, and improved stability. Moreover, relative ease of large-scale manufacturing compared to traditional approach and low storage requirement are anticipated to be present few key market opportunities.

According to the World Health Organization, ~18 million deaths occurred due to the unavailability of effective treatment for infectious disease in 2014, which demonstrates the global burden of infectious disease, providing an opportunity for DNA vaccine manufacturers. Moreover, rapid development in the field of molecular biology, immunology, and DNA synthesis is further expected to drive the growth of this market. Factors that may lead to increased demand for DNA vaccines include inefficient drug therapies and increased microbial resistance to existing antimicrobials and antibiotics treatments in the future.

Vaccines used currently are composed of killed pathogen or live attenuated viruses, whereas DNA vaccines consist of the DNA sequence of the antigen, which is administered in humans to stimulate an immune response. This approach offers a number of potential advantages over traditional approaches, including the stimulation of both B- and T-cell responses, improved vaccine stability, the absence of any infectious agent, and the relative ease of large-scale manufacture. In addition, DNA vaccines are temperature stable, leading to easier storage and transport. DNA vaccination may provide an important tool for stimulating an immune response in HBV, HCV, and HIV patients, owing to their therapeutic potential for ongoing chronic viral infection. For instance, Inovios INO-3112 is in phase II clinical trial, and can be used to treat cervical cancer caused by HPV. This immunotherapy enables the body to produce E6 and E7 antigens to induce a stronger targeted immune response against HPV-associated diseases, such as cervical cancer.

Get Access to TOC / Sample Report @ https://www.alliedmarketresearch.com/request-sample/2309

Key Findings of the Potential Analysis of Human DNA Vaccines Market:

• North America is expected to dominate the market in 2020, and is projected to grow at the highest CAGR during the forecast period.
• Europe is the second largest potential market, and is expected to grow at a CAGR of 9.0%.

The major players profiled in the global potential analysis of human DNA vaccines market are Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.